In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in
Preprint
Abstract
Non-viral gene editing offers a practical alternative to viral delivery for durable biologics production. Clinical trials have shown that adeno-associated virus encoding broadly neutralizing antibodies can protect against HIV, but result in limited, short-lived responses. The development of non-viral gene editing approaches in hematopoietic stem and progenitor cells holds promise for long-term antibody production. In this study, we evaluated CRISPR/Cas9 and CRISPR/Cas12a for gene knock-in at the immunoglobulin heavy chain locus in non-human primate hematopoietic stem and progenitor cells. Delivering the nuclease as a protein alongside a custom DNA template, we optimized editing with Cas12a and demonstrated higher knock-in efficiency and fewer non-specific edits than Cas9. Transplantation of edited non-human primate hematopoietic stem and progenitor cells into MISTRG mice led to engraftment, B cell differentiation, and transgene expression of a reporter transgene or anti-HIV antibody after HIV immunization with detectable anti-HIV antibody titers in peripheral blood circulation. These findings demonstrate the feasibility of using non-viral gene editing in HSPC as a potential strategy for sustained biologics production in the treatment of chronic diseases such as HIV. Future work will assess the efficacy of this model in a non-human primate model of HIV infection.Keywords
Funding Information
- Office of the Director (P51 OD010425, U42 OD011123)
- National Cancer Institute (P30 CA015704 (RRID:SCR_022606, RRID:SCR_022610, RRID:SCR_022613))
- National Institute of Allergy and Infectious Diseases (R01 AI167009)
- Bill & Melinda Gates Foundation (INV002613)
This publication has 55 references indexed in Scilit:
- Impact of CRISPR/HDR editing versus lentiviral transduction on long-term engraftment and clonal dynamics of HSPCs in rhesus macaquesCell Stem Cell, 2024
- Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cellsCell Stem Cell, 2022
- Engineering of the CMV promoter for controlled expression of recombinant genes in HEK293 cellsBiotechnology Journal, 2022
- In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery MethodsMolecular Therapy Nucleic Acids, 2019
- Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor TemplatesMolecular Therapy, 2019
- MISTRG mice support engraftment and assessment of nonhuman primate hematopoietic stem and progenitor cellsExperimental Hematology, 2019
- Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editingWIREs RNA, 2018
- In Vivo Murine-Matured Human CD3 + Cells as a Preclinical Model for T Cell-Based ImmunotherapiesMolecular Therapy - Methods & Clinical Development, 2017
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- Epstein‐barr virus‐related herpesvirus from a rhesus monkey (Macaca Mulatta) with malignant lymphomaInternational Journal of Cancer, 1986